Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Intercept Pharmaceuticals |
---|---|
Information provided by: | Intercept Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00501592 |
The primary objectives of this study are to assess, in patients with Type 2 diabetes mellitus (DM) and presumed nonalcoholic fatty liver disease (NAFLD), the following:
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Type II Fatty Liver |
Drug: INT-747 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Exploratory Study of INT-747 in Patients With Type 2 Diabetes Mellitus and Presumed Nonalcoholic Fatty Liver Disease |
Estimated Enrollment: | 36 |
Study Start Date: | July 2007 |
Estimated Study Completion Date: | September 2008 |
Estimated Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
25 mg
|
Drug: INT-747
25 mg PO QD, 50 mg PO QD, Placebo PO QD
|
2: Experimental
50 mg
|
Drug: INT-747
25 mg PO QD, 50 mg PO QD, Placebo PO QD
|
3: Placebo Comparator
Placebo
|
Drug: INT-747
25 mg PO QD, 50 mg PO QD, Placebo PO QD
|
This is a multi-center, double-blind, randomized, placebo-controlled, multiple-dose, parallel-group study. Three (3) cohorts of 12 patients each will receive either placebo, 25 mg INT-747, or 50 mg INT-747 by mouth daily for 6 weeks.
The primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43). Other endpoints will be evaluated by monitoring adverse experiences; vital signs; clinical laboratory values; plasma drug and metabolite concentrations; and general health and well-being.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
UC San Diego VAMC | Recruiting |
San Diego, California, United States, 92161 | |
Contact: Paivi M Burke 858-642-3997 paivi.burke@va.gov | |
Principal Investigator: Sunder Mudaliar, MD | |
United States, Texas | |
Diabetes & Glandular Disease Research Associates, Inc. | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: Mark Kipnes, M.D. 210-615-5555 | |
Principal Investigator: Mark Kipnes, M.D. | |
United States, Virginia | |
Virginia Commonwelath University | Recruiting |
Richmond, Virginia, United States, 23298 | |
Contact: Sherry Boyett 804-828-5434 slboyett@vcu.edu | |
Principal Investigator: Arun J Sunyal, MD |
Study Director: | David A Shapiro, M.D. | Intercept Pharmaceuticals |
Responsible Party: | Intercept Pharmaceuticals ( David A. Shapiro, MD - Chief Medical Officer, Intercept Pharmaceuticals ) |
Study ID Numbers: | 747-203 |
Study First Received: | July 13, 2007 |
Last Updated: | April 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00501592 |
Health Authority: | United States: Food and Drug Administration |
Farnesoid X receptor agonist Metabolic Disorder Diabetes NAFLD |
Liver Diseases Non-alcoholic steatohepatitis (NASH) Digestive System Diseases Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus |
Endocrine System Diseases Fatty Liver Endocrinopathy Metabolic disorder Glucose Metabolism Disorders |